In 2018, Bailly et al. compared the use of HCL with conventional subcutaneous insulin among a population of 136 hospitalized patients with T2D for a maximum period of 15 days, with an increase of 24% in TIR (65.8% vs. 41.5%), a reduction of mean BG levels and glycemic variability [62]. Here, INS is linked to type 2 diabetes mellitus.